abstract |
The present invention provides quinoline / quinoxaline compounds that inhibit platelet-derived growth factor or p56 lck tyrosine kinase activity, pharmaceutical compositions comprising such compounds, and cell differentiation, proliferation, extracellular matrix generation or mediator release and / or T It relates to the use of such compounds in treating patients suffering from or capable of suffering from disorders / conditions associated with cell activation and proliferation. |